Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period

被引：58

作者：

Chen, Guang-Hou ^{[1
]}

Wang, Guo-Bin ^{[1
]}

Huang, Fan ^{[1
]}

Qin, Rong ^{[2
]}

Yu, Xiao-Jun ^{[1
]}

Wu, Ruo-Lin ^{[1
]}

Hou, Liu-Jin ^{[1
]}

Ye, Zheng-Hui ^{[1
]}

Zhang, Xing-Hua ^{[1
]}

Zhao, Hong-Chuan ^{[1
]}

机构：

[1] Anhui Med Univ, Organ Transplantat Ctr, Dept Gen Surg, Affiliated Hosp 1, 218 Jixi Rd, Hefei 230022, Peoples R China

[2] Anhui Med Univ, Dept Pathol, Affiliated Hosp 2, Hefei 230601, Peoples R China

来源：

TRANSPLANT IMMUNOLOGY | 2021年 / 66卷

关键词：

Liver transplantation; Immune checkpoint inhibitors; PD-1; Graft rejection; Case report;

D O I：

10.1016/j.trim.2021.101386

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immune checkpoint inhibitors are increasingly used in the treatment of various solid tumors, including hepatocellular carcinoma (HCC). For liver transplant recipients, the safety of using immune checkpoint inhibitors before or after transplantation remains to be further explored. Former reports were mainly about posttransplant use of immune checkpoint inhibitors resulting in allograft rejection. Here we present one HCC patient who received toripalimab (an immune checkpoint inhibitor currently in phase 3 clinical trial for HCC) therapy before undergoing liver transplantation. He finally suffered fatal acute hepatic necrosis which is likely to be related to the acute immune rejection caused by the pretransplant use of toripalimab.

引用

页数：3

共 5 条

[1] 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejectio
Demetris, A. J.
Bellamy, C.
Hubscher, S. G.
O'Leary, J.
Randhawa, P. S.
Feng, S.
Neil, D.
Colvin, R. B.
McCaughan, G.
Fung, J. J.
Del Bello, A.
Reinholt, F. P.
Haga, H.
Adeyi, O.
Czaja, A. J.
Schiano, T.
Fiel, M. I.
Smith, M. L.
Sebagh, M.
Tanigawa, R. Y.
Yilmaz, F.
Alexander, G.
Baiocchi, L.
Balasubramanian, M.
Batal, I.
Bhan, A. K.
Bucuvalas, J.
Cerski, C. T. S.
Charlotte, F.
de Vera, M. E.
ElMonayeri, M.
Fontes, P.
Furth, E. E.
Gouw, A. S. H.
Hafezi-Bakhtiari, S.
Hart, J.
Honsova, E.
Ismail, W.
Itoh, T.
Jhala, N. C.
Khettry, U.
Klintmalm, G. B.
Knechtle, S.
Koshiba, T.
Kozlowski, T.
Lassman, C. R.
Lerut, J.
Levitsky, J.
Licini, L.
Liotta, R.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (10) : 2816 - 2835
[2] Liver graft rejection following immune checkpoint inhibitors treatment: a review
Hu, Bo
Yang, Xiao-Bo
Sang, Xin-Ting
[J]. MEDICAL ONCOLOGY, 2019, 36 (11)
[3] Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
Nordness, Mina F.
Hamel, Stephanie
Godfrey, Caroline M.
Shi, Chanjuan
Johnson, Douglas B.
Goff, Laura W.
O'Dell, Heather
Perri, Roman E.
Alexopoulos, Sophoclis P.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (03) : 879 - 883
[4] Comparison of Immunological Responses of Plague Vaccines F1+rV270 and EV76 in Chinese-Origin Rhesus Macaque, Macaca mulatta
Qiu, Y.
Liu, Y.
Qi, Z.
Wang, W.
Kou, Z.
Zhang, Q.
Liu, G.
Liu, T.
Yang, Y.
Yang, X.
Xin, Y.
Li, C.
Cui, B.
Huang, S.
Liu, H.
Zeng, L.
Wang, Z.
Yang, R.
Wang, H.
Wang, X.
[J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2010, 72 (05) : 425 - 433
[5] Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction
Shi, Xiao-Lei
Mancham, Shanta
Hansen, Bettina E.
de Knegt, Robert J.
de Jonge, Jeroen
van der Laan, Luc J. W.
Rivadeneira, Fernando
Metselaar, Herold J.
Kwekkeboom, Jaap
[J]. JOURNAL OF HEPATOLOGY, 2016, 64 (06) : 1274 - 1282

← 1 →